Journal article Open Access
Dr. Reem Abdul Raheem Mirdan
Women complained from several physiological and biochemical disturbances when they become aged and loss adequate amount of estradiol hormone secreted from ovarian follicles. The present study was conducted to evaluate the concentration of some available clotting factors and feminizing hormone (estradiol hormone) in menopausal women . A total number of participants postmenopausal women werre sixty (60) women and their ages were 50 to 69 years old and fifteen (15) premenopausal women, their ages (control group) that they have normal menstruation cycle and whose ages ranged between 20 – 25 years old. The aging women (menopause) were subdivided according to their ages periods into four groups, the first group (50 – 54 years), second group (55 – 59years), third group (60 - 64 years), and fourth group (65 – 69 years). Values of estradiol hormone recorded a significant drop in all groups of postmenopausal women in matching with counter parts of premenopausal women. About prothrombin time (PT), its results showed a remarkable elevation (p<0.05) in all groups of menopausal women when compared with control group. Values of intrinsic pathway test (activated partial thromboplastin time) indicated remarkable increase (p<0.05) in all tested groups (menopausal women) compared to control group. About clotting factors, levels of fibrinogen (FI) concentrations did significantly progressive elevated (p<0.05) in all postmenopausal women groups in matching with those of control group. Also, concentrations of stable factor (VII) were significantly increased ( p<0.05) , whereas antihemophilic factors (VIII) and Christmas factor (IX) pointed out a significant progressive fall (p<0.05) of (Any groups of aging women should be determined) aging women in a comparison with premenopausal women. In conclusion, deficiency of estradiol hormone in postmenopausal women appears associated with fluctuation of clotting factor concentrations and these disturbances can give an indicator that estradiol hormone maintain hemostatic mechanism to prevent risk of cardio- vascular problems.